Disc Medicine FY2029 EPS Forecast Lowered by HC Wainwright

Disc Medicine, Inc. (NASDAQ:IRON - Free Report) - Research analysts at HC Wainwright dropped their FY2029 earnings per share estimates for shares of Disc Medicine in a research report issued on Thursday, May 8th. HC Wainwright analyst D. Tsao now anticipates that the company will post earnings per share of $5.86 for the year, down from their prior estimate of $6.36. HC Wainwright has a "Buy" rating and a $118.00 price objective on the stock. The consensus estimate for Disc Medicine's current full-year earnings is ($4.07) per share.

A number of other brokerages also recently commented on IRON. Stifel Nicolaus lifted their price objective on Disc Medicine from $90.00 to $94.00 and gave the stock a "buy" rating in a research report on Friday, January 24th. TD Cowen started coverage on Disc Medicine in a report on Thursday, February 27th. They set a "buy" rating on the stock. Wedbush reissued an "outperform" rating and set a $90.00 price target (up previously from $83.00) on shares of Disc Medicine in a research report on Tuesday, January 21st. Morgan Stanley reaffirmed an "overweight" rating and set a $85.00 target price on shares of Disc Medicine in a research note on Friday, March 7th. Finally, Cantor Fitzgerald boosted their target price on shares of Disc Medicine from $99.00 to $132.00 and gave the company an "overweight" rating in a report on Tuesday, March 18th. Ten investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Disc Medicine currently has a consensus rating of "Buy" and an average target price of $93.80.

Disc Medicine Price Performance

IRON opened at $44.24 on Monday. The firm has a market capitalization of $1.53 billion, a price-to-earnings ratio of -11.12 and a beta of 0.77. The company's 50 day simple moving average is $46.93 and its two-hundred day simple moving average is $54.98. Disc Medicine has a 1-year low of $30.65 and a 1-year high of $68.73.

Disc Medicine (NASDAQ:IRON - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($1.02) earnings per share for the quarter, missing the consensus estimate of ($0.99) by ($0.03).

Insider Buying and Selling at Disc Medicine

In other Disc Medicine news, Director Mona Ashiya sold 202,146 shares of the company's stock in a transaction on Monday, March 10th. The stock was sold at an average price of $54.29, for a total transaction of $10,974,506.34. Following the transaction, the director now directly owns 208,742 shares in the company, valued at $11,332,603.18. This represents a 49.20% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Jean M. Franchi sold 3,136 shares of Disc Medicine stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $54.58, for a total value of $171,162.88. Following the completion of the sale, the chief financial officer now directly owns 69,530 shares of the company's stock, valued at $3,794,947.40. The trade was a 4.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 356,290 shares of company stock worth $19,336,901 over the last three months. Insiders own 4.24% of the company's stock.

Hedge Funds Weigh In On Disc Medicine

Hedge funds have recently bought and sold shares of the company. Barclays PLC increased its stake in Disc Medicine by 123.7% during the third quarter. Barclays PLC now owns 40,145 shares of the company's stock worth $1,972,000 after purchasing an additional 22,202 shares during the period. JPMorgan Chase & Co. grew its holdings in shares of Disc Medicine by 16.1% in the third quarter. JPMorgan Chase & Co. now owns 16,255 shares of the company's stock valued at $799,000 after purchasing an additional 2,257 shares in the last quarter. SG Americas Securities LLC increased its stake in Disc Medicine by 66.0% during the 4th quarter. SG Americas Securities LLC now owns 8,076 shares of the company's stock worth $512,000 after buying an additional 3,212 shares during the period. China Universal Asset Management Co. Ltd. lifted its holdings in Disc Medicine by 10.4% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,310 shares of the company's stock worth $400,000 after buying an additional 593 shares in the last quarter. Finally, Bleakley Financial Group LLC purchased a new position in Disc Medicine in the 4th quarter valued at approximately $486,000. Institutional investors and hedge funds own 83.70% of the company's stock.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.